Antibody

11개 · ADC 882 · Antibody 4071 · CGT 2714 · 자동 수집 갱신 권장 · 9월 2일

PopularRecently updatedCuratedMost trialsNeeds refreshORRLatestPhase 3FDA approved11 programs

데이터 갱신 주기입니다. 갱신 대기 7,666개 보기 · Curated Core는 주간 자동 동기화됩니다.

AntibodyLimited DatastaleBristol-Myers SquibbPhase 2

Lirilumab (Lirilumab)

Non-Hodgkin's Lymphoma; Hodgkin Lymphoma · Squamous Cell Carcinoma of the Head and

#SquamousCellCarcinomaoftheHeadan#Antibody#Phase2#monoclonal-antibody#Non-HodgkinsLymphoma+2
Trials 13Status Active
AntibodyLimited DatastaleAmgenPhase 2

MT103 (Blinatumomab, Blinatumomab (MT103))

Non-Hodgkin's Lymphoma, Relapsed · Acute Lymphoblastic Leukemia

#AcuteLymphoblasticLeukemia#Antibody#Phase2#monoclonal-antibody#Non-HodgkinsLymphoma+2
Trials 2Status Active
AntibodyLimited DatastaleGenzyme, a Sanofi CompanyPhase 2

alemtuzumab (CAMPATH, CAMPATH (alemtuzumab))

Non-Hodgkin's Lymphoma · Non-Hodgkin's Lymphoma

#Non-HodgkinsLymphoma#Antibody#Phase2#monoclonal-antibody#Genzyme
Trials 1Status Discontinued
AntibodyLimited DatastaleHeidelberg UniversityPhase 2

Cyclophosphamide, Pentostatin, Rituximab (Cyclophosphamide, Pentostatin, Rituximab)

Immunocytoma/Morbus Waldenström; B-Cell Non-Hodgkin's Lymphoma · Immunocytoma/Morbus Waldenström

#ImmunocytomaMorbusWaldenstrm#Antibody#Phase2#monoclonal-antibody#Immunocytoma+3
Trials 1Status Active
AntibodyLimited DatastaleRochePhase 2

Pegylated Liposomal Doxorubicin (Doxil, Pegylated Liposomal Doxorubicin, Pegylated Liposomal Doxorubicin (Doxil) and Rituximab)

Non-Hodgkin's Lymphoma; Burkitt Lymphoma · Non-Hodgkin's Lymphoma

#Non-HodgkinsLymphoma#Antibody#Phase2#monoclonal-antibody#BurkittLymphoma+1
Trials 1Status Discontinued
AntibodyLimited DatastaleGerman High-Grade Non-Hodgkin's…Phase 3

R-CHOEP 14 with 12x Rituximab (R-CHOEP 14 with 12x Rituximab)

Non-Hodgkin's Lymphoma (NHL) · Non-Hodgkin's Lymphoma (NHL)

#Non-HodgkinsLymphomaNHL#Antibody#Phase3#monoclonal-antibody#German
Trials 1Status Active
AntibodyLimited DatastaleRochePhase 2

bevacizumab, Rituximab (bevacizumab, Rituximab)

Non-Hodgkin's Lymphoma; B-cell Lymphoma · Non-Hodgkin's Lymphoma

#Non-HodgkinsLymphoma#Antibody#Phase2#monoclonal-antibody#B-cellLymphoma+1
Trials 1Status Discontinued
AntibodyLimited DatastaleCTI BioPharmaPhase 3

fludarabine and rituximab (fludarabine and rituximab)

Non-Hodgkin's Lymphoma · Non-Hodgkin's Lymphoma

#Non-HodgkinsLymphoma#Antibody#Phase3#monoclonal-antibody#CTI
Trials 1Status Discontinued
AntibodyLimited DatastaleCTI BioPharmaPhase 3

fludarabine, rituximab, pixantrone (fludarabine, rituximab, pixantrone)

Non-Hodgkin's Lymphoma · Non-Hodgkin's Lymphoma

#Non-HodgkinsLymphoma#Antibody#Phase3#monoclonal-antibody#CTI
Trials 1Status Discontinued
AntibodyLimited DatastaleRochePhase 2

RO5072759 (obinutuzumab, obinutuzumab (RO5072759))

Non-Hodgkin's Lymphoma · Non-Hodgkin's Lymphoma

#Non-HodgkinsLymphoma#Antibody#Phase2#monoclonal-antibody#Roche
Trials 1Status Active
AntibodyLimited DatastaleAIDS Malignancy ConsortiumPhase 2

yttrium Y 90 ibritumomab tiuxetan (yttrium Y 90 ibritumomab tiuxetan)

AIDS-related Lymphoma; Adult Non-Hodgkin's Lymphoma · AIDS-related Lymphoma

#AIDS-relatedLymphoma#Antibody#Phase2#monoclonal-antibody#AdultNon-HodgkinsLymphoma+1
Trials 1Status Discontinued